News

News Back to resource centre 24 November 2022 Cambridge Cognition unveils strategic partnership for Chinese market expansion Cambridge Cognition is pleased to announce an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare

News Back to resource centre 11 January 2023 Cambridge Cognition and Winterlight Labs join forces to lead in voice and digital biomarkers for clinical trials Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce its acquisition of Winterlight, a leader in monitoring cognitive impairment through free-speech analysis.Both Cambridge Cognition and Winterlight share a

News Back to resource centre 24 November 2022 Cambridge Cognition unveils strategic partnership for Chinese market expansion Cambridge Cognition is pleased to announce an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare

News Back to resource centre 12 October 2022 Cambridge Cognition strengthens virtual clinical trials offering with eClinicalHealth acquisition Cambridge Cognition has entered an agreement to acquire eClinicalHealth Ltd; a full-service digital technology provider that is working on virtual clinical trials for three of the world’s top ten largest pharmaceutical companies.Catalysed by the pandemic, the overall virtual clinical trials market has

News Back to resource centre 12 October 2022 Cambridge Cognition strengthens virtual clinical trials offering with eClinicalHealth acquisition Cambridge Cognition has entered an agreement to acquire eClinicalHealth Ltd; a full-service digital technology provider that is working on virtual clinical trials for three of the world’s top ten largest pharmaceutical companies.Catalysed by the pandemic, the overall virtual clinical trials market has

News Back to resource centre 17 August 2022 Cambridge Cognition selected by the University of Oxford as a cognitive assessment partner for the ISAP study Alzheimer’s disease validation for NeuroVocalixTMCambridge Cognition is pleased to announce that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid Positivity (“ISAP”) study. As

News Back to resource centre 28 July 2022 CANTAB to be used in US Department of Defense PTSD trial We are pleased to announce two agreements in a new therapeutic area for Cambridge Cognition, post-traumatic stress disorder (“PTSD”). Most recently, a research agreement was entered into with the United States Department of Defense, following on from a contract secured earlier

News Back to resource centre 18 July 2022 Join us at AAIC 2022 We are looking forward to attending this year’s Alzheimer’s Association International Conference (AAIC) in San Diego from 31st July to 4th August and learning about the latest developments in dementia research.Meet us at Booth 108 to try out our tech and meet the scientists behind itCome and

News Back to resource centre 14 July 2022 2022 CANTAB Research Grant winners announced It has been another highly competitive year for our CANTABTM Research Grant, with the large number of high-quality applications making picking just three winners a challenge for our judging panel! Here we reveal the winning grants.The winners each receive a CANTABTM Connect Research Licence with 150

News Back to resource centre 31 May 2022 Cambridge Cognition partners on ambitious project for digital measurement of Alzheimer’s disease and related dementia symptoms Cambridge Cognition is pleased to announce that they have joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measure Development project. As a partner of this innovative, collaborative effort, Cambridge Cognition will